Sabine Chlosta

560 total citations
8 papers, 425 citations indexed

About

Sabine Chlosta is a scholar working on Pathology and Forensic Medicine, Oncology and Genetics. According to data from OpenAlex, Sabine Chlosta has authored 8 papers receiving a total of 425 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Pathology and Forensic Medicine, 5 papers in Oncology and 4 papers in Genetics. Recurrent topics in Sabine Chlosta's work include Lymphoma Diagnosis and Treatment (6 papers), Chronic Lymphocytic Leukemia Research (4 papers) and Cancer Immunotherapy and Biomarkers (3 papers). Sabine Chlosta is often cited by papers focused on Lymphoma Diagnosis and Treatment (6 papers), Chronic Lymphocytic Leukemia Research (4 papers) and Cancer Immunotherapy and Biomarkers (3 papers). Sabine Chlosta collaborates with scholars based in United States, Italy and France. Sabine Chlosta's co-authors include Arun Balakumaran, Yayan Zhang, Vincent Ribrag, Philippe Armand, Pier Luigi Zinzani, Margaret A. Shipp, John Kuruvilla, Craig H. Moskowitz, Jean‐Marie Michot and Douglas S. Fishman and has published in prestigious journals such as Blood, Infection and Immunity and Annals of Oncology.

In The Last Decade

Sabine Chlosta

8 papers receiving 423 citations

Peers

Sabine Chlosta

ONCOL

PFM

HEMAT

IMMUN

GENET

Vivien Mak China

Katarzyna Kapelko‐Słowik Poland

Takanobu Morishita Japan

Nathalie Mourad France

Yibin Jiang China

Cornelis E. Hack Netherlands

Paul J. Hengeveld Netherlands

Ji‐Young Lim South Korea

Ira L. Kraft United States

Jing L. Marantz United States

Vivien Mak China

Sabine Chlosta

177 ×0.7

ONCOL

256 ×1.7

PFM

65 ×0.4

HEMAT

130 ×0.9

IMMUN

45 ×0.4

GENET

Citations per year, relative to Sabine Chlosta Sabine Chlosta (= 1×) peers Vivien Mak

Countries citing papers authored by Sabine Chlosta

Since Specialization

Citations

This map shows the geographic impact of Sabine Chlosta's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sabine Chlosta with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sabine Chlosta more than expected).

Fields of papers citing papers by Sabine Chlosta

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sabine Chlosta. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sabine Chlosta. The network helps show where Sabine Chlosta may publish in the future.

Co-authorship network of co-authors of Sabine Chlosta

This figure shows the co-authorship network connecting the top 25 collaborators of Sabine Chlosta. A scholar is included among the top collaborators of Sabine Chlosta based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sabine Chlosta. Sabine Chlosta is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

8 of 8 papers shown

Zinzani, Pier Luigi, Vincent Ribrag, Craig H. Moskowitz, et al.. (2017). PHASE 1B STUDY OF PEMBROLIZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY PRIMARY MEDIASTINAL LARGE B‐CELL LYMPHOMA (RRPMBCL): UPDATED RESULTS FROM THE KEYNOTE‐013 TRIAL. Hematological Oncology. 35(S2). 189–190. 4 indexed citations

Zinzani, Pier Luigi, Vincent Ribrag, Craig H. Moskowitz, et al.. (2017). Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma. Blood. 130(3). 267–270. 218 indexed citations

Zinzani, Pier Luigi, Catherine Thiéblemont, В Я Мельниченко, et al.. (2017). Efficacy and safety of pembrolizumab in relapsed/refractory primary mediastinal large B‐cell lymphoma (rrPMBCL): interim analysis of the KEYNOTE‐170 phase 2 trial. Hematological Oncology. 35(S2). 62–63. 16 indexed citations

Michot, Jean‐Marie, Philippe Armand, Vincent Ribrag, et al.. (2016). Pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma (rrPMBCL) or relapsed or refractory Richter syndrome (rrRS): Phase 2 KEYNOTE-170 study. Annals of Oncology. 27. vi325–vi325. 1 indexed citations

Garcia‐Manero, Guillermo, Martin S. Tallman, Giovanni Martinelli, et al.. (2016). Pembrolizumab, a PD-1 Inhibitor, in Patients with Myelodysplastic Syndrome (MDS) after Failure of Hypomethylating Agent Treatment. Blood. 128(22). 345–345. 46 indexed citations

Michot, Jean‐Marie, Philippe Armand, Vincent Ribrag, et al.. (2016). KEYNOTE-170: Phase 2 study of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma (rrPMBCL) or relapsed or refractory Richter syndrome (rrRS). Annals of Oncology. 27. viii15–viii15. 2 indexed citations

Zinzani, Pier Luigi, Vincent Ribrag, Craig H. Moskowitz, et al.. (2016). Phase 1b Study of Pembrolizumab in Patients with Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Results from the Ongoing Keynote-013 Trial. Blood. 128(22). 619–619. 11 indexed citations

Chlosta, Sabine, Douglas S. Fishman, Erin E. Johnson, et al.. (2006). The Iron Efflux Protein Ferroportin Regulates the Intracellular Growth ofSalmonella enterica. Infection and Immunity. 74(5). 3065–3067. 127 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact